Urinary Biomarkers in Bladder Cancer: FDA-Approved Tests and Emerging Tools for Diagnosis and Surveillance
Cancers · 25.10.2025 · 17 (21) · 3425
DOI: 10.3390/cancers17213425 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 25.10.2025. Verfasst von Zhenyun Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, School of Medicine, University of California, Riverside, CA 92521, USA. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Internal Medicine, University of California Riverside School of Medicine.
Abstract (Originalsprache)
Bladder cancer is a prevalent malignancy with high morbidity and mortality, particularly when diagnosed at an advanced stage. Early detection is critical, as it significantly improves prognosis and the patient’s outcomes. Bladder cancer also has a high recurrence rate, necessitating long-term surveillance. While cystoscopy remains the gold standard for diagnosis and monitoring, it is invasive and costly. Urine cytology, though widely used, has high specificity for detecting high-grade urothelial carcinoma but suffers from low sensitivity and limited effectiveness as a stand-alone diagnostic tool. Urinary biomarkers offer a promising, noninvasive alternative for early detection and disease surveillance. This review examines FDA-approved urinary biomarker tests, including NMP 22, UroVysion, and BTA, highlighting their clinical utility and limitations. Additionally, we explore emerging biomarkers such as DNA methylation assays, genomic alterations, and proteomic signatures as well as advanced technologies like next-generation sequencing and machine learning-based platforms. These innovations have the potential to enhance diagnostic accuracy, risk stratification, and recurrent monitoring, ultimately improving early detection and long-term disease management. By evaluating both established and emerging urinary biomarkers, this review aims to provide clinicians and researchers with insights into evolving tools for bladder cancer diagnosis and surveillance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, School of Medicine, University of California, Riverside, CA 92521, USA.
- Pathology and Laboratory Medicine Service, VA Greater Los Angeles, Los Angeles, CA 90073, USA.
Förderung
- Department of Internal Medicine, University of California Riverside School of Medicine
Zitieren
APA
Yang, Z., Song, F., & Zhong, J. (2025). Urinary Biomarkers in Bladder Cancer: FDA-Approved Tests and Emerging Tools for Diagnosis and Surveillance. Cancers, 17(21), 3425. https://doi.org/10.3390/cancers17213425
Vancouver
Yang Z, Song F, Zhong J. Urinary Biomarkers in Bladder Cancer: FDA-Approved Tests and Emerging Tools for Diagnosis and Surveillance. Cancers. 2025;17(21):3425. doi:10.3390/cancers17213425
BibTeX
@article{Yang2025,
author = {Yang, Zhenyun and Song, Fengyu and Zhong, Jin},
title = {Urinary Biomarkers in Bladder Cancer: FDA-Approved Tests and Emerging Tools for Diagnosis and Surveillance},
journal = {Cancers},
year = {2025},
volume = {17},
number = {21},
pages = {3425},
doi = {10.3390/cancers17213425}
}
EUVIMED